Hengrui 1.3 billion "shopping"!

Not only Hengrui Pharmaceuticals and Dalian Wanchun, but also CSPC and Corning Jerry, Zhenbaodao and Henokang and other large pharmaceutical companies have entered into cooperation

"Find a good medicine"

Sun Piaoyang is full of Hengrui's innovation

The cooperation with Dalian Wanchun has also been regarded by the outside world as Hengrui Pharmaceuticals is leveraging local emerging pharmaceutical companies to break through innovative research and development, and it is also Sun Piaoyang's plan to implement his good medicine

Pranabrin is a new synthetic chemical entity that can activate the immune defense protein guanine nucleotide exchange factor (GEF-H1), accelerate the maturation of dendritic cells (DC cells) and promote antigen presentation, and directly activate T cells kill tumor cells and act as the "ignition agent of the immune system"

This year, the NDA application for the CIN indications of pranablin has been accepted by the United States and China successively and has been granted priority review qualifications

At the same time, Punabulin is also a high-value variety

In the 2021 semi-annual report, Hengrui Medicine fully disclosed its latest product pipeline, covering the follow-up main clinical R&D pipelines of marketed innovative drugs, the main clinical R&D pipelines of innovative drugs under research, and the main clinical R&D pipelines of overseas innovative drugs.

Hengrui Medicine also stated in the semi-annual report that the company urgently needs to concentrate resources to achieve rapid breakthroughs in innovation and internationalization

Accelerating integration of local companies

The battle for innovation resources starts

  Cooperating with innovative pharmaceutical companies emerging locally is not just a choice for Hengrui Pharmaceuticals

  On May 19, 2020, Zhenbaodao Pharmaceutical announced to pay Henuo Kang a transfer fee (including tax) consisting of a milestone payment of 150 million yuan and a sales commission of 6% of the annual net sales revenue, which was developed by the latter Related rights and interests of blockbuster anti-influenza drugs

  Behind the "marriage" actions of local pharmaceutical companies, on the one hand, there are hidden turbulences in the pharmaceutical market; on the other hand, it also proves that the innovation and comprehensive strength of domestic pharmaceutical companies have been continuously improved and they have excellent strength

  At a press conference held by the State Council Information Office on July 27, the Ministry of Science and Technology revealed that China's basic research accounted for more than 6% of R&D investment for the first time, and the original innovation capability of science and technology has been greatly improved

  In the eyes of the outside world, the cooperation between large local pharmaceutical companies and innovative companies is a representative case of biotech companies realizing the commercial value of product pipelines in advance under the background of "involving" domestic innovative drugs

  For large local pharmaceutical companies, innovative pharmaceutical companies have a richer variety of innovative products, as well as stronger early-stage R&D capabilities and talent reserves.

  China's billion-dollar healthcare market has also attracted global pharmaceutical giants to actively cooperate with local innovative companies for commercialization
.
CStone Pharmaceuticals previously announced that it will jointly develop lorlatinib with Pfizer for c-rosoncogene 1 (ROS1)-positive advanced non-small cell carcinoma (NSCLC)
.
In addition, Cinda Biopharmaceuticals and Eli Lilly have jointly developed the PD-1 inhibitor Sintilimab
.
As large local pharmaceutical companies also cooperate with innovative pharmaceutical companies to compete for innovation resources, the tide is rising, and domestic drug innovation is about to set off an even more fierce battle for innovation
.